|
1
|
Hayden JB and Hoang BH: Osteosarcoma:
basic science and clinical implications. Orthop Clin North Am.
37:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Henry LR, Lee HO, Lee JS, et al: Clinical
implications of fibroblast activation protein in patients with
colon cancer. Clin Cancer Res. 13:1736–1741. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Javidroozi M, Zucker S and Chen WT: Plasma
seprase and DPP4 levels as markers of disease and prognosis in
cancer. Dis Markers. 32:309–320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen SJ and Jiaang WT: Current advances
and therapeutic potential of agents targeting dipeptidyl
peptidases-IV, −II, 8/9 and fibroblast activation protein. Curr Top
Med Chem. 11:1447–1463. 2011.PubMed/NCBI
|
|
5
|
Dohi O, Ohtani H, Hatori M, et al:
Histogenesis-specific expression of fibroblast activation protein
and dipeptidylpeptidase-IV in human bone and soft tissue tumours.
Histopathology. 55:432–440. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rettig WJ, Garin-Chesa P, Beresford HR,
Oettgen HF, Melamed MR and Old LJ: Cell-surface glycoproteins of
human sarcomas: differential expression in normal and malignant
tissues and cultured cells. Proc Natl Acad Sci USA. 85:3110–3114.
1988. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ghersi G, Zhao Q, Salamone M, Yeh Y,
Zucker S and Chen WT: The protease complex consisting of dipeptidyl
peptidase IV and seprase plays a role in the migration and invasion
of human endothelial cells in collagenous matrices. Cancer Res.
66:4652–4661. 2006. View Article : Google Scholar
|
|
8
|
Cohen SJ, Alpaugh RK, Palazzo I, et al:
Fibroblast activation protein and its relationship to clinical
outcome in pancreatic adenocarcinoma. Pancreas. 37:154–158. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goscinski MA, Suo ZH, Nesland JM, et al:
Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen
activator expression in dysplasia and invasive squamous cell
carcinoma of the esophagus. A study of 229 cases from Anyang Tumor
Hospital, Henan Province, China. Oncology. 75:49–59. 2008.
View Article : Google Scholar
|
|
10
|
Keane FM, Nadvi NA, Yao TW and Gorrell MD:
Neuropeptide Y, B-type natriuretic peptide, substance P and peptide
YY are novel substrates of fibroblast activation protein-alpha.
FEBS J. 278:1316–1332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kennedy A, Dong H, Chen D and Chen WT:
Elevation of seprase expression and promotion of an invasive
phenotype by collagenous matrices in ovarian tumor cells. Int J
Cancer. 124:27–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kraman M, Bambrough PJ, Arnold JN, et al:
Suppression of antitumor immunity by stromal cells expressing
fibroblast activation protein-alpha. Science. 330:827–830. 2010.
View Article : Google Scholar
|
|
13
|
Yi YM, Zhang G, Zeng J, et al: A new tumor
vaccine: FAPtau-MT elicits effective antitumor response by
targeting indolamine2,3-dioxygenase in antigen presenting cells.
Cancer Biol Ther. 11:866–873. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sarto-Jackson I, Milenkovic I, Smalla KH,
et al: The cell adhesion molecule neuroplastin-65 is a novel
interaction partner of gamma-aminobutyric acid type A receptors. J
Biol Chem. 287:14201–14214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Danilova N: The evolution of adaptive
immunity. Adv Exp Med Biol. 738:218–235. 2012. View Article : Google Scholar
|
|
16
|
Liu C, Lewis CM, Lou Y, et al: Agonistic
antibody to CD40 boosts the antitumor activity of adoptively
transferred T cells in vivo. J Immunother. 35:276–282. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikuchi S, Iwai M, Sakurai-Yageta M, et
al: Expression of a splicing variant of the CADM1 specific to small
cell lung cancer. Cancer Sci. 103:1051–1057. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee G, Cheung AP, Ge B, et al: CA215 and
GnRH receptor as targets for cancer therapy. Cancer Immunol
Immunother. 61:1805–1817. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang WG, Hiscox S, Hallett MB, Scott C,
Horrobin DF and Puntis MC: Inhibition of hepatocyte growth
factor-induced motility and in vitro invasion of human colon cancer
cells by gamma-linolenic acid. Br J Cancer. 71:744–752. 1995.
View Article : Google Scholar
|
|
20
|
Estecha A, Aguilera-Montilla N,
Sánchez-Mateos P and Puig-Kröger A: RUNX3 regulates intercellular
adhesion molecule 3 (ICAM-3) expression during macrophage
differentiation and monocyte extravasation. PLoS One. 7:e333132012.
View Article : Google Scholar
|
|
21
|
Fujita-Hamabe W and Tokuyama S: The
involvement of cleavage of neural cell adhesion molecule in
neuronal death under oxidative stress conditions in cultured
cortical neurons. Biol Pharm Bull. 35:624–628. 2012. View Article : Google Scholar
|
|
22
|
Meeusen JW, Klein CJ, Pirko I, et al:
Potassium channel complex autoimmunity induced by inhaled brain
tissue aerosol. Ann Neurol. 71:417–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Christiansen VJ, Jackson KW, Lee KN, Downs
TD and McKee PA: Targeting inhibition of fibroblast activation
protein-alpha and prolyl oligopeptidase activities on cells common
to metastatic tumor microenvironments. Neoplasia. 15:348–358.
2013.
|
|
24
|
Hayward SW: Preclinical assessment of
fibroblast activation protein as a target for antitumor therapy.
Future Oncol. 6:347–349. 2010. View
Article : Google Scholar
|
|
25
|
Puré E: The road to integrative cancer
therapies: emergence of a tumor-associated fibroblast protease as a
potential therapeutic target in cancer. Expert Opin Ther Targets.
13:967–973. 2009.PubMed/NCBI
|
|
26
|
Santos AM, Jung J, Aziz N, Kissil JL and
Puré E: Targeting fibroblast activation protein inhibits tumor
stromagenesis and growth in mice. J Clin Invest. 119:3613–3625.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu R, Li H, Liu L, et al: Fibroblast
activation protein: A potential therapeutic target in cancer.
Cancer Biol Ther. 13:123–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cheng JD, Valianou M, Canutescu AA, et al:
Abrogation of fibroblast activation protein enzymatic activity
attenuates tumor growth. Mol Cancer Ther. 4:351–360.
2005.PubMed/NCBI
|
|
29
|
Scanlan MJ, Raj BK, Calvo B, et al:
Molecular cloning of fibroblast activation protein alpha, a member
of the serine protease family selectively expressed in stromal
fibroblasts of epithelial cancers. Proc Natl Acad Sci USA.
91:5657–5661. 1994. View Article : Google Scholar
|
|
30
|
Wesley UV, Albino AP, Tiwari S and
Houghton AN: A role for dipeptidyl peptidase IV in suppressing the
malignant phenotype of melanocytic cells. J Exp Med. 190:311–322.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ramirez-Montagut T, Blachere NE,
Sviderskaya EV, et al: FAPalpha, a surface peptidase expressed
during wound healing, is a tumor suppressor. Oncogene.
23:5435–5446. 2004. View Article : Google Scholar
|
|
32
|
Bauer S, Jendro MC, Wadle A, et al:
Fibroblast activation protein is expressed by rheumatoid
myofibroblast-like synoviocytes. Arthritis Res Ther. 8:R1712006.
View Article : Google Scholar
|
|
33
|
Goodman JD, Rozypal TL and Kelly T:
Seprase, a membranebound protease, alleviates the serum growth
requirement of human breast cancer cells. Clin Exp Metastasis.
20:459–470. 2003. View Article : Google Scholar
|
|
34
|
Chen H, Yang WW, Wen QT, Xu L and Chen M:
TGF-beta induces fibroblast activation protein expression;
fibroblast activation protein expression increases the
proliferation, adhesion, and migration of HO-8910PM [corrected].
Exp Mol Pathol. 87:189–194. 2009.PubMed/NCBI
|
